## 2 Results
### Overlapping Features
\begin{table}
\begin{tabular}{c c c c c c} \hline \hline \(m/z\) & \
\begin{tabular}{c} **Retention Time** \\ **(min)** \\ \end{tabular} & **Adduct** &
\begin{tabular}{c} **Monoisotopic** \\ **Mass** \\ \end{tabular} & **AUC** & **Tentative Identification** \\ \hline
311.1464 & 3.40 & [M + NH\({}_{4}\)]\({}^{+}\) & 293.1111 & 0.75 & 4-Hydroxylproline galactoside; 3 other hits \\ \hline
524.3710 & 14.21 & [M + H]\({}^{+}\) & 523.3638 & 0.72 & Platelet-activating factor; 4 other hits \\ \hline
263.0887 & 6.70 & [M + Na]\({}^{+}\) & 240.0998 & 0.72 &
\begin{tabular}{c} 3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid; 4 other hits \\ \end{tabular} \\ \hline
641.5110 & 20.65 & [M + NH\({}_{4}\)]\({}^{+}\) & 623.4761 & 0.71 & Cer(d16:1/6 keto-PGF1 alpha); 58 other hits \\ \hline
830.5664 & 19.88 & [M + Na]\({}^{+}\) & 807.5778 & 0.71 &
\begin{tabular}{c} PC(20:4(5Z,7E,11Z,14Z)-OH(9)/P-18:1(9Z)); \\ 151 other hits \\ \end{tabular} \\ \hline
769.4224 & 21.08 & [M + Na]\({}^{+}\) & 746.4370 & 0.70 &
\begin{tabular}{c} PG(-12:0/20:4(6Z,8E,10E,14Z)-2 OH(5S,12R)); \\ 5 other hits \\ \end{tabular} \\ \hline
188.0707 & 2.35 & [M + H]\({}^{+}\) & 187.0633 & 0.70 & Indoleacrylic acid \\ \hline
813.6839 & 21.40 & [M + H]\({}^{+}\) & 812.6771 & 0.68 & SM(d18:2(4E,14Z)/24:0); 1 other hit \\ \hline
377.2659 & 13.29 & [M + Na]\({}^{+}\) & 354.2770 & 0.68 & Glyceryl monolinoleate \\ \hline
343.2241 & 11.17 & [M + Na]\({}^{+}\) & 320.2351 & 0.67 & 12-HETE; 39 other hits \\ \hline \hline \end{tabular}
\end{table} 
Table 4: Top 10 tentatively identified endogenous metabolites for low vs. moderate skin disease activity. \begin{table}
\begin{tabular}{c c c c c} \hline \hline \(m/z\) & \
\begin{tabular}{c} **Retention Time** \\ **(min)** \\ \end{tabular} & **Adduct** &
\begin{tabular}{c} **Monoisotopic** \\ **Mass** \\ \end{tabular} & **AUC** & **Tentative Identification** \\ \hline
211.1441 & 3.90 & [M + NH\({}_{4}\)]\({}^{+}\) & 193.1103 & 0.60 & (R)-N-Methylslasholinol; 3 other hits \\ \hline
215.1279 & 4.78 & [M + H]\({}^{+}\) & 214.1205 & 0.58 & undec-3-enedio acid; 3 other hits \({}^{*}\) \\ \hline
769.4224 & 21.08 & [M + Na]\({}^{+}\) & 746.4370 & 0.57 &
\begin{tabular}{c} PG(20:4(8Z,11Z,14Z,17Z)-2 OH(55,6R)/i-12:0); \\ 5 other hits \\ \end{tabular} \\ \hline
760.5845 & 20.22 & [M + H]\({}^{+}\) & 759.5778 & 0.57 & Pe-NMe2(20:1(11Z)/15:0); 26 other hits \\ \hline
802.5350 & 19.32 & [M + Na]\({}^{+}\) & 779.5465 & 0.57 &
\begin{tabular}{c} PC(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/P-16:0); \\ 89 other hits \\ \end{tabular} \\ \hline
496.3397 & 12.95 & [M + Na]\({}^{+}\) & 473.3505 & 0.57 & Clupanodonyl carnitineine; 5 other hits \\ \hline
544.3373 & 13.35 & [M + Na]\({}^{+}\) & 521.3481 & 0.56 & LysoPC(18:1(9Z)/0:0); 5 other hits \\ \hline
518.3215 & 12.95 & [M + Na]\({}^{+}\) & 495.3325 & 0.56 & LysoPC(16:0/0:0); 2 other hits \\ \hline
351.2504 & 12.67 & [M + Na]\({}^{+}\) & 328.2614 & 0.56 & MG(0:0/16:1(9Z)/0:0); 1 other hit \\ \hline
828.5507 & 19.67 & [M + Na]\({}^{+}\) & 805.5621555 & 0.56 &
\begin{tabular}{c} PC(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/P-18:1(9Z)); \\ 107 other hits \\ \end{tabular} \\ \hline \hline \end{tabular}
\end{table} 
Table 3: Top 10 tentatively identified endogenous metabolites for moderate vs. high skin disease activity. \begin{table}
\begin{tabular}{c c c c c} \hline \hline \(m/z\) & \
\begin{tabular}{c} **Retention Time** \\ **(min)** \\ \end{tabular} & **Adduct** &
\begin{tabular}{c} **Monoisotopic** \\ **Mass** \\ \end{tabular} & **AUC** & **Tentative ID** \\ \hline
212.0026 & 3.97 & [M + H]\({}^{-}\) & 213.0096 & 0.72 & Indoxyl sulfate; 3 other hits \\ \hline
729.1788 & 11.02 & [M + Cl]\({}^{-}\) & 694.2109 & 0.69 & Neocusutoside C; 3 other hits \\ \hline
464.3020 & 7.39 & [M - H]\({}^{-}\) & 465.3090 & 0.67 & Glyco-beta-muricholic acid; 5 other hits \\ \hline
802.5614 & 13.14 & [M - H]\({}^{-}\) & 803.5676 & 0.67 & PE(PGF1 alpha/P-18:0); 38 other hits \\ \hline
343.1707 & 8.15 & [M - H]\({}^{-}\) & 344.1776 & 0.64 & Tamoxifen-ol \\ \hline \hline \end{tabular}
\end{table}